3 results about "Mucic acid" patented technology

The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and / or salt co-crystals are also provided.

The present application relates to the technical field of oil and gas field acid liquid, in particular to an integrated three-dimensional variable viscosity acid system and a preparation method thereof, the temperature-resistant and salt-resistant polyacrylamide copolymer prepared by the present application can form a three-dimensional network structure by introducing strong polar groups such as sulfonic acid groups and amide groups, the structure can maintain high viscosity under high temperature and high salt environment through molecular chain stretching, and the viscosity is reduced at low temperature to realize the characteristics of three-dimensional variable viscosity; secondly, the sulfonic acid group of 2-acrylamide-2-methylpropanesulfonic acid has strong salt resistance, the cyclic structure of acryloyl morpholine can enhance the rigidity and thermal stability of the molecular chain, and polyvinyl alcohol fiber can be used as a physical crosslinking point to improve the shear resistance of the system through hydrogen bonding, and the synergistic effect of the three can make the prepared integrated three-dimensional variable viscosity acid system have a more stable molecular structure.

The object is achieved according to the invention by oxidising galacturonic acid in an aqueous solution in vitro with a dehydrogenase having NAD(P)+ as cofactor to form reduced cofactor NAD(P)H, wherein the reduced cofactor NAD(P)H is oxidised with an NAD(P)H oxidase, characterised in that the NAD(P)H oxidase for the oxidation of NAD(P)H to NAD(P)+ comprises an amino acid sequence selected from the group consisting of: i) an amino acid sequence having at least 80% identity to SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16 or SEQ ID No. 18, ii) an amino acid sequence encoded by a nucleic acid having at least 80% identity to SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15 or SEQ ID No. 17, and iii) an amino acid sequence encoded by a nucleic acid that binds under stringent conditions to a complementary strand of a nucleic acid molecule having the nucleic acid sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, or SEQ ID No. 17.